NHRA grants Gulf Biotech Company licence to produce injectable drugs

TDT | Manama

The Daily Tribune – www.newsofbahrain.com

Gulf Biotech Company has become the first licenced facility in Bahrain for manufacturing injection medicines, the National Health Regulatory Authority said yesterday. In the first phase, production will focus on 56 pharmaceutical products. Gulf Biotech Company, established in 2015 with Bahraini/ Saudi investment amounting to 80 million dollars, and based in the Bahrain International Park in Hidd, is a pioneer in the generic drug industry.

Bahrain Pharma, which received a licence in 2019, is the first factory for medicines and vitamins. Gulf Biotech obtained a licence to produce sterile and injectable formulations, which will be subjected to final inspection to grant a Good Manufacturing Practice certificate to start the production.

The certificate ensures that products are manufactured consistently and controlled according to quality standards. “The authority was keen that the factory fulfils conditions related to security, safety and quality following international standards,” Dr Maryam Al Jalahma, the CEO of the NHRA, said.

Bosch (Isolator system)

The facility, with an area of 4,500 square metres, aims at producing injectable formulations such as vials, ampoules and prefilled syringes. Dr Riyadh Al-Ashban said the factory has production lines from the German company Bosch (Isolator system), which guarantees complete technical work without human intervention. The factories also intend to produce medicines unavailable in the Arabian Gulf and in great demand.